Health Care Market Oversight

MedImpact and Maxor

The Health Care Market Oversight (HCMO) program reviews health care business deals to make sure they support Oregon's goals of health equity, lower costs, increased access, and better care. On November 3, 2026, the Oregon Health Authority (OHA) accepted a complete notice of material change describing plans for MedImpact Healthcare Services, Inc. ("MedImpact") to acquire certain subsidiaries of Maxor Acquisition, Inc. ("Maxor").

Who's involved?

MedImpact is a national, independent pharmacy benefit manager (PBM). MedImpact is the fifth largest PBM in the nation, handling about 5% of prescriptions in the nation. MedImpact provides third party administrator services to clients mostly through PBM, cash card, rebate aggregator, 340B program, and mail order pharmacy services. In 2025, MedImpact generated over $500 million in revenue from Oregon clients. MedImpact processed almost 6 million prescriptions in Oregon in 2025, serving over 800,000 people.

Maxor is the parent company of Maxor National Pharmacy Services, LLC, which (together with its subsidiaries and affiliates) operates **VytlOne**, a national, independent PBM. VytlOne has no Oregon-based PBM clients but served over 3,600 people in Oregon in 2025 through out-of-state clients. Additionally, Maxor provides specialty pharmacy and 340B services and owns Gateway Health Partners, Inc., a rebate aggregator for PBMs. Maxor is majority owned by TowerBrook Capital Partners, a private equity company.

About the deal

MedImpact is proposing to acquire the VytlOne PBM and Gateway rebate aggregator businesses from Maxor. The transaction does not include Maxor's business segment that provides specialty pharmacy and 340B optimization services. The entities do not expect any changes to services or access for patients.

What's next?

OHA is reviewing this deal to understand how it could affect access to care for communities in Oregon. During the review, OHA will use health care data, news and media reports, information from the entities, and public input to decide whether the deal should be approved. After completing a review, OHA will issue a decision about whether the deal may proceed as planned.

We want to hear from you!

Public input helps us understand how this deal could help or harm people in your community. To share your thoughts about this deal, please email hcmo.info@oha.oregon.gov, leave a voicemail at 503-945-6161, or fill out the public comment form. In your comment, mention "MedImpact", what you think, and whether you support or oppose the deal.

You can get this document in other languages, large print, braille, or a format you prefer free of charge. Contact us by email at hcmo.info@oha.oregon.gov or by phone at 503-945-6161. We accept all relay calls.

November 3, 2026

OREGON HEALTH AUTHORITY